Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study.

Tribouilloy C, Rusinaru D, Maréchaux S, Jeu A, Ederhy S, Donal E, Réant P, Arnalsteen E, Boulanger J, Ennezat PV, Garban T, Jobic Y.

Circulation. 2012 Dec 11;126(24):2852-8. doi: 10.1161/CIRCULATIONAHA.112.111260. Epub 2012 Nov 9.

2.

Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.

Tribouilloy C, Maréchaux S, Jobic Y, Jeu A, Ederhy S, Donal E, Réant P, Arnalsteen E, Boulanger J, Garban T, Ennezat PV, Andréjak M, Rusinaru D.

Eur Heart J. 2013 Dec;34(46):3580-7. doi: 10.1093/eurheartj/eht266. Epub 2013 Sep 6.

PMID:
24014218
3.

Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.

Maréchaux S, Jeu A, Jobic Y, Ederhy S, Donal E, Réant P, Abouth S, Arnasteen E, Boulanger J, Ennezat PV, Garban T, Szymanski C, Tribouilloy C.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):349-56. doi: 10.1016/j.acvd.2013.04.006. Epub 2013 May 31.

4.

[Benfluorex and valvular heart disease].

Tribouilloy C, Jeu A, Maréchaux S, Jobic Y, Rusinaru D, Andréjak M.

Presse Med. 2011 Nov;40(11):1008-16. doi: 10.1016/j.lpm.2011.09.001. Epub 2011 Oct 5. Review. French.

PMID:
21981882
5.

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL.

JAMA. 2000 Apr 5;283(13):1703-9.

PMID:
10755496
6.

Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.

Weill A, Païta M, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H.

Pharmacoepidemiol Drug Saf. 2010 Dec;19(12):1256-62. doi: 10.1002/pds.2044. Epub 2010 Oct 13.

PMID:
20945504
7.

[About the settlement of litigations concerning the harm caused by benfluorex (Mediator®)].

Nicot P, Frachon I, Hill C.

Presse Med. 2013 Apr;42(4 Pt 1):411-8. doi: 10.1016/j.lpm.2013.02.310. Epub 2013 Mar 11. Review. French.

PMID:
23490638
8.

Restrictive organic mitral regurgitation associated with benfluorex therapy.

Tribouilloy C, Rusinaru D, Henon P, Tribouilloy L, Leleu F, Andréjak M, Sevestre H, Peltier M, Caus T.

Eur J Echocardiogr. 2010 Aug;11(7):614-21. doi: 10.1093/ejechocard/jeq027. Epub 2010 Mar 17.

PMID:
20237052
9.

How can benfluorex-related heart valve disease be identified by echocardiography?

Tribouilloy C, Rusinaru D, Andréjak M.

Arch Cardiovasc Dis. 2011 Oct;104(10):489-92. doi: 10.1016/j.acvd.2011.07.001. Epub 2011 Sep 28. No abstract available.

10.

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.

Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE.

N Engl J Med. 1998 Sep 10;339(11):719-24.

11.

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.

Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT.

N Engl J Med. 1998 Sep 10;339(11):713-8.

12.

The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.

Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL.

Ann Intern Med. 2001 Feb 20;134(4):261-6.

PMID:
11182835
13.

Food and Drug Administration criteria for the diagnosis of drug-induced valvular heart disease in patients previously exposed to benfluorex: a prospective multicentre study.

Maréchaux S, Rusinaru D, Jobic Y, Ederhy S, Donal E, Réant P, Arnalsteen E, Boulanger J, Garban T, Ennezat PV, Jeu A, Szymanski C, Tribouilloy C.

Eur Heart J Cardiovasc Imaging. 2015 Feb;16(2):158-65. doi: 10.1093/ehjci/jeu212. Epub 2014 Nov 2.

PMID:
25368209
14.

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.

Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ.

Am J Cardiol. 1999 Dec 1;84(11):1335-8.

PMID:
10614800
15.

Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.

Burger AJ, Charlamb MJ, Singh S, Notarianni M, Blackburn GL, Sherman HB.

Int J Cardiol. 2001 Jul;79(2-3):159-65.

PMID:
11461737
16.

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.

Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F, Subramaniam P, Glancy DL.

Obes Res. 1999 Jul;7(4):313-22.

17.

Operative finding of aortic cusp prolapse in benfluorex-induced aortic regurgitation.

Ennezat PV, Bruneval P, Maréchaux S, Bellemin JP, Senellart F, Arnaud-Crozat E, Ramadan R, Obadia JF, Touati G, Fleury JP, Tribouilloy C.

Int J Cardiol. 2015;186:231-2. doi: 10.1016/j.ijcard.2015.03.191. Epub 2015 Mar 18. No abstract available.

PMID:
25828122
18.

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD, Constantine GD, Reid CL.

JAMA. 2001 Oct 24-31;286(16):2011-4.

PMID:
11667938
19.

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.

Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T.

Circulation. 2000 May 2;101(17):2071-7.

Supplemental Content

Support Center